Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

Metabolic Technologies

Status and phase: Completed; Phase 1

Conditions: Healthy Subjects

Treatments: Dietary Supplement: PeakATP 250; Dietary Supplement: PeakATP 400 plus proprietary blend; Dietary Supplement: Placebo; Dietary Supplement: PeakATP 400

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01141504

MTI2010-CS01

Details and patient eligibility

About

Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of ATP may have a positive impact on repeated muscle contractions. The current study will test the hypothesis that increasing ATP availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.

Full description

To date we have studied 10 subjects who have followed through with all 3 of the original interventions (Placebo, 250 mg PeakATP/d and 400 mg PeakATP/d). Currently we have received approval and are expanding the study with 5 additional subjects who will receive the Placebo, 400 mg PeakATP/d and the 400 mg PealATP/d plus proprietary blend interventions.

Enrollment: 16 patients

Sex: All

Ages: 20 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• No major medical conditions;
• Able to perform fatigue testing procedures;
• Not currently taking prescription medications;
• Not currently taking dietary supplements (a daily multi-vitamin not exceeding RDA is permitted)

Exclusion criteria

• Major medical condition affecting metabolism or general function;
• Not able to perform fatigue testing;
• Taking prescription medications;
• Taking a dietary supplement other than a multi-vitamin not exceeding RDA

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

16 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Oral placebo capsules similar in color and size to the intervention

Treatment:

Dietary Supplement: Placebo

PeakATP 250

Active Comparator group

Description:

Oral supplement capsules containing 250 mg/day of PeakATP

Treatment:

Dietary Supplement: PeakATP 250

PeakATP 400

Active Comparator group

Description:

Oral supplement capsules containing 400 mg/day of PeakATP

Treatment:

Dietary Supplement: PeakATP 400

PeakATP 400 plus proprietary blend

Active Comparator group

Description:

Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend

Treatment:

Dietary Supplement: PeakATP 400 plus proprietary blend